November 28 (SeeNews) - Bulgarian veterinary drug maker Biovet [BUL:53B] said on Monday its consolidated net profit rose to 11.9 million levs ($6.4 million/6.1 million euro) in the first nine months of 2016, from 6.3 million levs in the corresponding period of last year.
Sales revenue in the January-September period grew to 159.2 million levs, from 141.3 million levs in the first nine months of 2015, the company said in its nine-month financial report filed with the Sofia bourse.
Operating expenses in the review period increased to 143.8 million levs, from 127.1 million levs last year.
Biovet’s operating profit rose to 15.4 million levs, compared to 14.2 million levs in the first nine months of last year.
Biovet said earlier this month that its majority owner Huvepharma and minority shareholder Opportunity 2009 had submitted to minority shareholders an offer of 15.11 levs per share for the remaining 9.99% stake they do not already own.
Biovet traded flat at 15.03 levs on the Sofia bourse on Monday, as 15 shares changed hands.
(1 euro = 1.95583 levs)